Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912949 · ClinicalTrials.gov registry record · Phase 2
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
A Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion, sponsored by Partner Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT02912949: Active Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion, sponsored by Partner Therapeutics.
NCT02912949 is a Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion that is active but no longer recruiting, run by Partner Therapeutics. The registered enrollment target is 250 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02912949, a Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion, is active but no longer recruiting, sponsored by Partner Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Primary Outcome
Evaluation of clinical benefit assessed by RECIST v1.1 determining objective overall response rate (ORR)
Conditions Studied
Interventions
- DRUG zenocutuzumab (MCLA-128)
Study Locations (20)
California
- The Oncology Institute of Hope and Innovation - Cerritos
- University of California Irvine - Irvine
- Stanford University - Palo Alto
- Sharp Memorial Hospital - San Diego
Florida
- Memorial Cancer Institute - Hollywood
- Cancer Specialists of North Florida - Jacksonville
- Mayo Clinic - Jacksonville
Montana
- Billings Clinic Cancer Center - Billings
- St. James Healthcare - Butte
Arizona
- Mayo Clinic - Phoenix
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Emory Winship Cancer Institute - Atlanta
Illinois
- Northwest Oncology & Hematology - Rolling Meadows
Massachusetts
- Dana Farber Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT02912949 still lists
NCT02912949 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher).
The record links to 4 conditions, with Solid Tumours Harboring NRG1 Fusion appearing as the primary indexed condition, and to 1 intervention - of which zenocutuzumab (MCLA-128) is the first listed.
NCT02912949 names 20 study sites across 14 states, led by California, Florida, Montana.
Frequently Asked Questions
What is clinical trial NCT02912949 about?
NCT02912949 is a clinical study titled "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)". This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
What is the current status of trial NCT02912949?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2015-01. Estimated completion is 2026-12-31.
What conditions does trial NCT02912949 study?
This clinical trial studies the following conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion.
What interventions are being tested in trial NCT02912949?
The interventions under investigation include: zenocutuzumab (MCLA-128) (DRUG).
Who is sponsoring clinical trial NCT02912949?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02912949 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02912949's enrollment target sits among peer trials
250 222nd of 2000 higher than 1,768 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia